Azacitidine as maintenance therapy in pediatric de novo acute myeloid leukemia
Azacitidine maintenance therapy may sustain molecular remission in specific subgroups of pediatric AML, particularly CBF-AML patients with persistent MRD after induction who are ineligible for HSCT. However, the potential benefits must be weighed against the toxicity profile. The optimal dosing and scheduling require further investigation, and broader application warrants validation through larger, prospective, randomized controlled trials.
Authors
- Hao Zheng (ORCID: https://orcid.org/0000-0002-7834-8010)
- Nainong Li (ORCID: https://orcid.org/0000-0001-5620-5791)
- Chunxia Cai
- Mei Li (ORCID: https://orcid.org/0000-0001-9868-951X)
- Chunping Wu (ORCID: https://orcid.org/0000-0002-5386-3278)
- Yongzhi Zheng
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1696125
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province
- National Key Clinical Specialty Discipline Construction Program of China